Pharmaceutical News

Supreme Court Rejects Takeda and Eli Lilly Appeal in Actos RICO Case

June 8, 2020, Washington D.C. -- The United States Supreme Court has declined Takeda Pharmaceuticals and Eli Lilly Co.’s appeal of a lawsuit accusing both companies of defrauding patients and health benefit funds by failing to disclose that the diabetes drug Actos increases the risk of developing bladder cancer. Actos [...]

Ninth Circuit Revives Actos RICO Class Action Against Takeda and Eli Lilly

Dec. 3, 2019 – San Francisco, California - - Takeda Pharmaceuticals Company and Eli Lilly and Company will face revived class action claims after the U.S. Court of Appeals for the Ninth Circuit reversed a Central District of California court decision. The plaintiffs, a Minnesota-based healthcare fund and consumers from multiple [...]

Lawsuit Seeks Punitive Damages, Alleges Zantac Drug Makers Knew About NDMA Defect but Failed to Warn or Test

October 21, 2019, Los Angeles, California - -The national law firm of Baum Hedlund Aristei & Goldman has filed lawsuits against the manufacturers of Zantac, alleging the popular heartburn drug leads to the formation of a potent cancer-causing chemical, NDMA, at levels over 3,000 times greater than the Food and [...]

By |2020-06-09T15:30:12-07:00October 21st, 2019|Blog, Pharma News, Press Releases, R. Brent Wisner|

Celexa and Lexapro Fraud Lawsuit Gets Green Light from Appeals Court

The First Circuit Court of Appeals has reversed a district court’s dismissal of lawsuits filed by a mother and a trade union health care fund who alleged Forest Laboratories, Inc. (now part of Allergan) fraudulently induced them to buy Celexa and Lexapro for use in children and adolescents despite evidence the [...]

By |2019-04-19T10:43:53-07:00March 13th, 2019|Celexa News, Lexapro News, Pharma News|

Brent Wisner Named One of America’s Most Influential Trial Lawyers

Jan. 22, 2019 – Miami, Florida - - The National Law Journal and the Trial Lawyer Magazine named Baum, Hedlund, Aristei & Goldman attorney and partner, R. Brent Wisner, one of America’s 50 Most Influential Trial Lawyers for his success over the past year. The outstanding civil plaintiff and criminal [...]

Law360 Names BHAG Attorney Brent Wisner Titan of the Plaintiffs Bar

May 7, 2018 – Los Angeles, California - - Legal news media company Law360 named Baum, Hedlund, Aristei & Goldman attorney R. Brent Wisner a Titan of the Plaintiffs Bar. Wisner was one of ten attorneys Law360 profiled for earning significant legal victories in 2017. According to Law360, the attorneys [...]

By |2018-06-06T12:45:52-07:00May 7th, 2018|Blog, Paxil News, Pharma News, Press Releases, R. Brent Wisner|

Widow Maintains GSK Liable for Suicide in Paxil Lawsuit Appeal

March 1, 2018 – Chicago, Illinois — The widow of a Chicago lawyer who took his own life while taking a generic version of Paxil (paroxetine), a GlaxoSmithKline (GSK) antidepressant, told a federal appeals court that a jury’s verdict holding GSK liable for her husband’s suicide should stand. In the [...]

By |2018-04-11T10:51:38-07:00March 1st, 2018|Blog, Paxil News, Pharma News, Press Releases, R. Brent Wisner|

Researchers Seek Retraction of MD-18 Celexa Study

Feb. 23, 2018 – Los Angeles, California – A group of researchers sent a letter this week to Dr. Robert Freedman, Editor of the American Journal of Psychiatry, calling for the retraction of a Celexa study the researchers claim is rife with “serious misrepresentations.” The study, known as the MD-18 ‘Wagner’ [...]

Baum Hedlund Urges DOJ to Reopen Investigation re Celexa / Lexapro Clinical Trials

Boston, Massachusetts – February 8, 2018 - - The law firm of Baum, Hedlund, Aristei & Goldman has sent a letter and memorandum to the U.S. Attorney’s Office (USAO) for the District of Massachusetts calling for the reopening of its investigation and prosecution of Forest Laboratories Inc. and its subsidiary, [...]

Acthar Class Action Accuses Mallinckrodt of Inflating Price 85,000%

Los Angeles, California - - A class action lawsuit filed on behalf of numerous Medicare Advantage Organizations (MAOs) accuses pharmaceutical manufacturer Mallinckrodt (MNK) of engaging in a scheme to drastically inflate the price and reduce competition for its drug H.P. Acthar Gel (Acthar), a drug primarily prescribed for infants with [...]